Design and rationale for MAGNITUDE, a phase 3, randomised, placebo-controlled trial of NTLA-2001, a CRISPR-based gene editing therapy, in patients with transthyretin amyloidosis with cardiomyopathy

Back

HFA Premium Access

Design and rationale for MAGNITUDE, a phase 3, randomised, placebo-controlled trial of NTLA-2001, a CRISPR-based gene editing therapy, in patients with transthyretin amyloidosis with cardiomyopathy

Session: Myocardial disease - clinical 5

Topic: Clinical

Speaker: Doctor M. Maurer (New York, US)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Doctor Mathew Maurer

Columbia University Irving Medical Centre, New York (United States of America)

15 presentations

4 followers

7 more presentations in this session

T-Amylo score for the diagnosis of transthyretin cardiac amyloidosis in patients with acute heart failure.

Speaker: Ms M. Diez (Buenos Aires, AR)

Prevalence, clinical significance and prognosis value of liver stiffness measurement anomalies in transthyretin cardiac amyloidosis

Speaker: Mrs E. Lointier (Toulouse, FR)

Right ventricular to pulmonary artery uncoupling is an early predictor of poor outcome in wild-type transthyretin cardiac amyloidosis

Speaker: Doctor G. Sinigiani (Padova, IT)

Impairment of right ventricular to pulmonary artery coupling is associated with worse survival in cardiac amyloidosis

Speaker: Doctor A. Jakstaite (Hannover, DE)

Utility of KAsH score in predicting in-hospital mortality in takotsubo cardiomyopathy

Speaker: Doctor I. Martins Moreira (Vila Real, PT)

Access the full session

Myocardial disease - clinical 5

Speakers: Doctor M. Maurer, Ms M. Diez, Mrs E. Lointier, Doctor G. Sinigiani, Doctor A. Jakstaite...

Access

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources